Clinical Pharmacokinetics OnlineFirst articles

15-05-2024 | Review Article

Drugs in Human Milk Part 1: Practical and Analytical Considerations in Measuring Drugs and Metabolites in Human Milk

Human milk is a remarkable biofluid that provides essential nutrients and immune protection to newborns. Breastfeeding women consuming medications could pass the drug through their milk to neonates. Drugs can be transferred to human milk by …

Authors:: Osama Y. Alshogran, Prerna Dodeja, Hamdan Albukhaytan, Taylor Laffey, Nupur Chaphekar, Steve Caritis, Imam H. Shaik, Raman Venkataramanan

11-05-2024 | Dasatinib | Letter to the Editor

Comment on: “CYP3A4*22 Genotype‑Guided Dosing of Kinase Inhibitors in Cancer Patients”

Authors:: Thijs H. Oude Munnink, Saskia K. Klein, Daan J. Touw

Open Access 09-05-2024 | Insulins | Original Research Article

The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec

Impaired renal function is a common long-term complication of diabetes mellitus as up to 40% of individuals with diabetes develop chronic kidney disease [ 1 , 2 ]. It is well known that renal impairment can alter drug pharmacokinetics, potentially …

Authors:: Hanne Haahr, Blanka Cieslarová, Janne R. Hingst, Shan Jiang, Niels R. Kristensen, Viera Kupčová, Lea Nørgreen, Frank-Dietrich H. Wagner, Stanislav Ignatenko

04-05-2024 | Pharmacokinetics | Systematic Review

Population Pharmacokinetics of Intravenous Lidocaine in Adults: A Systematic Review

Intravenous (IV) lidocaine exhibits significant pharmacokinetic (PK) variability among individuals and has a low threshold for toxicity. However, several studies have reported an unclear or weak correlation between plasma concentrations and the …

Authors:: Keng Wah Foong, Sook Hui Chaw, Yoke Lin Lo, Pui San Loh

Open Access 02-05-2024 | Dolutegravir | Correction

Correction: Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers

Authors:: Lisanne A. H. Bevers, Anne E. M. Kamphuis, L. C. Wendy van der Wekken-Pas, Rory Leisegang, David M. Burger, Angela Colbers

Open Access 23-04-2024 | Achondroplasia | Original Research Article

Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model

Achondroplasia is the most common form of disproportionate short stature and is characterized by severe height deficit accumulated from a very young age [ 1 – 4 ]. People affected by achondroplasia have impaired endochondral bone growth causing …

Authors:: Yulan Qi, Ming Liang Chan, Diane R. Mould, Kevin Larimore, Elena Fisheleva, Anu Cherukuri, Jonathan Day, Ravi Savarirayan, Melita Irving, Carlos A. Bacino, Julie Hoover-Fong, Keiichi Ozono, Klaus Mohnike, William R. Wilcox, Michael B. Bober, Joshua Henshaw

Open Access 13-04-2024 | Milrinone | Original Research Article

Time-Varying Clearance in Milrinone Pharmacokinetics from Premature Neonates to Adolescents

Milrinone is a type III phosphodiesterase inhibitor that increases cardiac contractility and myocardial relaxation rate, and decreases systemic vascular resistance. It does not raise myocardial oxygen consumption nor increase heart rate, which are …

Authors:: Conor J. O’Hanlon, Anita Sumpter, Brian J. Anderson, Jacqueline A. Hannam

Open Access 07-04-2024 | Infliximab | Systematic Review

Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review

Monoclonal antibodies (mAbs) are an important therapeutic modality for conditions that commonly affect women of child-bearing potential, such as autoimmune disorders [ 1 ]. Although relatively little information is available on the pharmacokinetics …

Authors:: J. van Gendt, R. Emaus, M. C. Visschedijk, D. J. Touw, D. G. Bouwknegt, K. de Leeuw, J. R. Prins, P. Malik, Paola Mian

Open Access 06-04-2024 | Tacrolimus | Original Research Article

Tacrolimus Variability and Clinical Outcomes in the Early Post-lung Transplantation Period: Oral Versus Continuous Intravenous Administration

Tacrolimus-based immunosuppressive regimes are considered standard of care after lung transplantation (LuTx) [ 1 ]. Nonetheless, tacrolimus is known to have a narrow therapeutic range and high interindividual pharmacokinetic (PK) variability …

Authors:: Julia E. M. van Dommelen, Heleen Grootjans, Esther V. Uijtendaal, Dieuwertje Ruigrok, Bart Luijk, Matthijs van Luin, Wouter Bult, Dylan W. de Lange, Nuray Kusadasi, Joep M. Droogh, Toine C. G. Egberts, Erik A. M. Verschuuren, Maaike A. Sikma

Open Access 05-04-2024 | Pharmacokinetics | Original Research Article

Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors

Triple-negative breast cancer (TNBC), defined as a lack of tumor-cell expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) [ 1 ], accounts for approximately 15% of invasive breast cancers [ 2 – …4

Authors:: Abhishek G. Sathe, Indrajeet Singh, Pratap Singh, Paul M. Diderichsen, Xiaohui Wang, Peter Chang, Atiya Taqui, See Phan, Sandhya Girish, Ahmed A. Othman

04-04-2024 | Pharmacokinetics | Letter to the Editor

Comment on “Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies” and “High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints”

Authors:: Leping Kong, Jan-Willem C. Alffenaar, Sophie L. Stocker

Open Access 04-04-2024 | Dolutegravir | Original Research Article

Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers

Worldwide, approximately 1.5 million children younger than 15 years are estimated to be living with HIV (1). These children need lifelong treatment with antiretroviral therapy (ART) to prevent HIV-related morbidity and mortality. However, only 57% …

Authors:: Lisanne A. H. Bevers, Anne E. M. Kamphuis, L. C. Wendy van der Wekken-Pas, Rory Leisegang, David M. Burger, Angela Colbers

Open Access 26-03-2024 | Original Research Article

Personalized Antifungal Therapy Through Model-Informed Precision Dosing of Posaconazole

Posaconazole is a first-line antifungal agent for prophylaxis of various life-threatening invasive fungal diseases [ 1 , 2 ]. Additionally, posaconazole is deployed for antifungal therapy and was recently found to be non-inferior to voriconazole …

Authors:: Anouk M. E. Jansen, Kim Snijdelaar, Ron J. Keizer, Isabel Spriet, Erwin Dreesen, Roger J. M. Brüggemann, Rob ter Heine

Open Access 26-03-2024 | Tuberculosis | Original Research Article

Predictions of Bedaquiline Central Nervous System Exposure in Patients with Tuberculosis Meningitis Using Physiologically based Pharmacokinetic Modeling

Tuberculosis meningitis (TBM) develops when Mycobacterium tuberculosis (Mtb) disseminates from the primary pulmonary site of infection to the central nervous system (CNS) including the brain [ 1 ]. TBM, the most severe form of Mtb infections, is …

Authors:: Krina Mehta, Pavel Balazki, Piet H. van der Graaf, Tingjie Guo, J. G. Coen van Hasselt

Keynote webinar | Spotlight on medication adherence

Springer Medicine